Amgen Inc. (AMGN)
undefined
undefined%
At close: undefined
259.48
0.71%
Pre-market Jan 07, 2025, 05:55 AM EST

Amgen Inc. Revenue Breakdown

Quarter Sep 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Sep 30, 2020Jun 30, 2020Mar 31, 2020Sep 30, 2019Jun 30, 2019Mar 31, 2019Sep 30, 2018Jun 30, 2018Mar 31, 2018
Aranesp Revenue 337.00M 349.00M 319.00M 323.00M 365.00M 355.00M 348.00M 358.00M 357.00M 358.00M 362.00M 396.00M 367.00M 355.00M 384.00M 387.00M 422.00M 452.00M 436.00M 414.00M 477.00M 472.00M 454.00M
Aranesp Revenue Growth -3.44% +9.40% -1.24% -11.51% +2.82% +2.01% -2.79% +0.28% -0.28% -1.10% -8.59% +7.90% +3.38% -7.55% -0.78% -8.29% -6.64% +3.67% +5.31% -13.21% +1.06% +3.96% n/a
BLINCYTO Revenue 327.00M 244.00M 1.01B 1.03B 1.07B 579.00M 1.10B 1.11B 1.05B 862.00M 1.11B 1.29B 1.14B 924.00M 1.32B 1.25B 1.15B 1.37B 1.36B 1.15B 1.29B 1.30B 1.10B
BLINCYTO Revenue Growth +34.02% -75.96% -1.93% -3.09% +84.46% -47.27% -0.72% +5.23% +21.93% -22.20% -14.04% +12.67% +23.81% -30.26% +6.34% +8.07% -15.59% +0.22% +18.42% -10.91% -0.77% +17.83% n/a
ENBREL Revenue 825.00M 567.00M 350.00M 307.00M 281.00M 254.00M 325.00M 318.00M 317.00M 287.00M 284.00M 293.00M 280.00M 251.00M 260.00M 253.00M 280.00M 266.00M 267.00M 245.00M 532.00M 610.00M 494.00M
ENBREL Revenue Growth +45.50% +62.00% +14.01% +9.25% +10.63% -21.85% +2.20% +0.32% +10.45% +1.06% -3.07% +4.64% +11.55% -3.46% +2.77% -9.64% +5.26% -0.37% +8.98% -53.95% -12.79% +23.48% n/a
EVENITY Revenue 399.00M 342.00M 386.00M 349.00M 346.00M 358.00M 469.00M 288.00M 284.00M 266.00M 630.00M 609.00M 534.00M 476.00M 538.00M 561.00M 479.00M 630.00M 698.00M 592.00M 433.00M 452.00M 445.00M
EVENITY Revenue Growth +16.67% -11.40% +10.60% +0.87% -3.35% -23.67% +62.85% +1.41% +6.77% -57.78% +3.45% +14.04% +12.18% -11.52% -4.10% +17.12% -23.97% -9.74% +17.91% +36.72% -4.20% +1.57% n/a
KRYSTEXXA Revenue 310.00M 235.00M 629.00M 419.00M 310.00M 362.00M 616.00M 627.00M 594.00M 451.00M 873.00M 803.00M 814.00M 758.00M 701.00M 659.00M 654.00M 476.00M 499.00M 471.00M n/a n/a n/a
KRYSTEXXA Revenue Growth +31.91% -62.64% +50.12% +35.16% -14.36% -41.23% -1.75% +5.56% +31.71% -48.34% +8.72% -1.35% +7.39% +8.13% +6.37% +0.76% +37.39% -4.61% +5.94% n/a n/a n/a n/a
Kyprolis Revenue 378.00M 376.00M 1.11B 567.00M 600.00M 392.00M 992.00M 862.00M 922.00M 852.00M 273.00M 272.00M 286.00M 286.00M 205.00M 200.00M 229.00M n/a n/a n/a n/a n/a n/a
Kyprolis Revenue Growth +0.53% -66.03% +95.24% -5.50% +53.06% -60.48% +15.08% -6.51% +8.22% +212.09% +0.37% -4.90% 0.00% +39.51% +2.50% -12.66% n/a n/a n/a n/a n/a n/a n/a
Nplate Revenue 456.00M 317.00M 417.00M 986.00M 1.03B 927.00M 333.00M 309.00M 325.00M 329.00M 545.00M 517.00M 488.00M 468.00M 481.00M 435.00M 481.00M n/a n/a n/a n/a n/a n/a
Nplate Revenue Growth +43.85% -23.98% -57.71% -4.09% +10.90% +178.38% +7.77% -4.92% -1.22% -39.63% +5.42% +5.94% +4.27% -2.70% +10.57% -9.56% n/a n/a n/a n/a n/a n/a n/a
Otezla Revenue 564.00M 394.00M 527.00M 406.00M 424.00M 388.00M 484.00M 495.00M 533.00M 502.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Otezla Revenue Growth +43.15% -25.24% +29.80% -4.25% +9.28% -19.83% -2.22% -7.13% +6.18% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Prolia Revenue 1.04B 999.00M n/a 519.00M 530.00M 536.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Prolia Revenue Growth +4.60% n/a n/a -2.08% -1.12% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Repatha (evolocumab) Revenue 567.00M 517.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Repatha (evolocumab) Revenue Growth +9.67% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TEPEZZA Revenue 488.00M 424.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TEPEZZA Revenue Growth +15.09% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TEZSPIRE Revenue 269.00M 173.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TEZSPIRE Revenue Growth +55.49% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Vectibix Revenue 282.00M 247.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Vectibix Revenue Growth +14.17% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
XGEVA Revenue 541.00M 561.00M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
XGEVA Revenue Growth -3.57% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Quarter Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2011
Non-Us Revenue 8.38B 7.73B 7.79B 6.93B 6.14B 5.39B 4.82B 4.67B 4.50B 4.67B 4.20B 1.32B
Non-Us Revenue Growth +8.49% -0.73% +12.37% +12.87% +13.90% +11.80% +3.32% +3.78% -3.69% +11.22% +218.60% n/a
United States Revenue 19.81B 18.59B 18.19B 18.50B 17.22B 18.36B 18.03B 18.33B 17.17B 15.40B 14.48B 3.70B
United States Revenue Growth +6.51% +2.20% -1.63% +7.39% -6.18% +1.82% -1.62% +6.75% +11.50% +6.33% +291.25% n/a

Operating Expense Breakdown

Quarter Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018Mar 31, 2018Dec 31, 2017Sep 30, 2017Jun 30, 2017Mar 31, 2017Dec 31, 2016Sep 30, 2016Jun 30, 2016Mar 31, 2016Dec 31, 2015Sep 30, 2015Jun 30, 2015Mar 31, 2015
Selling, General, and Administrative Revenue 1.63B 1.78B 1.81B 2.27B 1.35B 1.29B 1.26B 1.57B 1.29B 1.33B 1.23B 1.43B 1.30B 1.38B 1.25B 1.77B 1.35B 1.29B 1.32B 1.51B 1.22B 1.26B 1.15B 1.56B 1.29B 1.35B 1.13B 1.43B 1.17B 1.21B 1.06B 1.32B 1.24B 1.29B 1.20B 1.42B 1.24B 1.16B 1.03B
Selling, General, and Administrative Revenue Growth -8.96% -1.27% -20.49% +68.07% +4.56% +2.86% -19.97% +22.14% -3.01% +8.06% -13.82% +9.20% -5.71% +10.37% -29.27% +31.72% +3.94% -1.60% -13.02% +23.71% -2.94% +9.19% -25.98% +20.57% -4.43% +20.05% -21.02% +21.97% -3.23% +13.63% -19.58% +6.35% -3.72% +7.40% -15.04% +13.83% +7.24% +13.06% n/a
Research and Development Revenue 1.45B 1.45B 1.34B 1.53B 1.08B 1.11B 1.06B 1.32B 1.11B 1.04B 959.00M 1.35B 1.42B 1.08B 967.00M 1.23B 1.06B 964.00M 952.00M 1.31B 1.00B 924.00M 879.00M 1.18B 926.00M 869.00M 760.00M 1.04B 877.00M 873.00M 769.00M 1.08B 990.00M 900.00M 872.00M 1.09B 1.12B 964.00M 894.00M
Research and Development Revenue Growth +0.21% +7.74% -12.45% +42.17% -3.05% +5.20% -20.09% +19.06% +7.03% +8.34% -28.86% -5.20% +31.42% +11.89% -21.32% +15.73% +10.17% +1.26% -27.44% +31.07% +8.33% +5.12% -25.63% +27.65% +6.56% +14.34% -27.13% +18.93% +0.46% +13.52% -28.66% +8.89% +10.00% +3.21% -20.22% -2.32% +16.08% +7.83% n/a

Create Price Alert on AMGN

Your price alert will notify you when the stock price is above 257.65.

Add to Watchlist